Twenty-three of the 27 mutated MN patients (85.2%) harbored at least one MDS-related adverse mutation, such as ASXL1, U2AF1, DNMT3A, p53, EZH2, BCOR. Here, DNMT3A is linked to myelodysplastic syndrome.